A Phase 3 interventional study of HU007 and Restasis in Dry Eye Syndrome, sponsored by Huons Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2020-05-08.
Sponsored by Huons Co., Ltd. (part of Huons Global) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Dry Eye Syndromes with a site in Korea, Republic of — 5 open to participants now, 6 under way, 1 of them phase 3. Dry Eye Syndromes · Korea, Republic of.
Among the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of, this one is the 10th largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2018, is one of 16 in phase 3, and was the 21st registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →5 of the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Huons Co., Ltd. · Sites in Korea, Republic of
Ages 19+
AJU Pharm Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Nu Eyne Co., Ltd. · Sites in Korea, Republic of
Ages 19–60
Hanlim Pharm. Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 40+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 14 · Phase 3 17 · Phase 4 7
First in 2008; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 209 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 99 across the 52 interventional studies, 275 across the 4 observational. Of the 44 that completed or were terminated, 2 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 58 have an industry lead sponsor. The 10 most frequent:
This study is registered under Huons Co., Ltd., one of the names counted as Huons Global. Under that name alone:
Huons Co., Ltd. is the lead sponsor of 29 studies on the registry; 5 are open to participants now.
Huons Global has 7 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
2 of the studies in Dry Eye Syndromes with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07397949Samsung Medical CenterRebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery | 2026-12 |
| NCT07656688Huons Co., Ltd.Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 58 studies in Dry Eye Syndromes with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multicenter, Randomized, Double blind, Restasis®-controlled Non-inferiority, Moisview® Eye Drops-controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients with Dry Eye Syndrome
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cyclosporine 0.02%, trehalose 3% 1 drop b.i.d at 12hr interval for 12 weeks
Drug: HU007
Cyclosporine 0.05% 1 drop b.i.d at 12hr interval for 12 weeks
Drug: Restasis
trehalose 3% 1 drop b.i.d at 12hr interval for 12 weeks
Drug: Moisview
change from Baseline in Corneal staining(Oxford grading) score
Time frame: Week 12
change from Baseline in Corneal staining(Oxford grading) score
Time frame: Week 4,8
change from Baseline of Conjunctival staining(Oxford grading) score
Time frame: Week 4,8,12
change from Baseline of Strip meniscometry assessment
Time frame: Week 4,8,12
change from Baseline of Tear film break-up time
Time frame: Week 4,8,12
change from Baseline of Standard patient evaluation of eye dryness questionnaire
Time frame: Week 4,8,12
arrival time of 100% clearence in Corneal staining test
Time frame: Week 0-12
The number of total rescue drug usage
Time frame: Week 0-12
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2018 to primary completion in Jul 2018, 5 months.
Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 5 months is below that.
Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HU007